Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
The gene encoding the receptor-tyrosine kinase RET was first discovered more than three
decades ago, and activating RET rearrangements and mutations have since been identified …
decades ago, and activating RET rearrangements and mutations have since been identified …
Sunitinib: from rational design to clinical efficacy
LQM Chow, SG Eckhardt - Journal of clinical oncology, 2007 - ascopubs.org
Sunitinib (SU011248) is an oral small molecular tyrosine kinase inhibitor that exhibits potent
antiangiogenic and antitumor activity. Tyrosine kinase inhibitors such as SU6668 and …
antiangiogenic and antitumor activity. Tyrosine kinase inhibitors such as SU6668 and …
KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation
M Miettinen, J Lasota - Applied immunohistochemistry & molecular …, 2005 - journals.lww.com
CD117 (KIT) is a type III receptor tyrosine kinase operating in cell signal transduction in
several cell types. Normally KIT is activated (phosphorylated) by binding of its ligand, the …
several cell types. Normally KIT is activated (phosphorylated) by binding of its ligand, the …
SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer
TJ Abrams, LB Lee, LJ Murray, NK Pryer… - Molecular cancer …, 2003 - AACR
The purpose of this study was to evaluate the activity of the indolinone kinase inhibitor
SU11248 against the receptor tyrosine kinase KIT in vitro and in vivo, examine the role of …
SU11248 against the receptor tyrosine kinase KIT in vitro and in vivo, examine the role of …
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
R Roskoski Jr - Biochemical and biophysical research communications, 2007 - Elsevier
Sunitinib (SU-11248, Sutent) inhibits at least eight receptor protein-tyrosine kinases
including vascular endothelial growth factor receptors 1–3 (VEGFR1–VEGFR3), platelet …
including vascular endothelial growth factor receptors 1–3 (VEGFR1–VEGFR3), platelet …
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies
MC Heinrich, CD Blanke, BJ Druker… - Journal of clinical …, 2002 - ascopubs.org
PURPOSE: Activation of the KIT tyrosine kinase by somatic mutation has been documented
in a number of human malignancies, including gastrointestinal stromal tumor (GIST) …
in a number of human malignancies, including gastrointestinal stromal tumor (GIST) …
Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000-2008
Isatin (1H-indole-2, 3-dione) and its derivatives demonstrate a diverse array of biological
and pharmacological activities including anticonvulsant, antibacterial, antifungal, antiviral …
and pharmacological activities including anticonvulsant, antibacterial, antifungal, antiviral …
Molecular genetics of lung cancer
Lung cancer results from multiple changes in the genome of susceptible pulmonary cells
caused by exposure to carcinogens found in tobacco smoke, the environment, or the …
caused by exposure to carcinogens found in tobacco smoke, the environment, or the …
Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRα, PDGFRβ, and Met in large-cell neuroendocrine carcinoma of the lung
Purpose Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a relatively
uncommon, high-grade neuroendocrine tumor sharing several features with small-cell lung …
uncommon, high-grade neuroendocrine tumor sharing several features with small-cell lung …
Normal and oncogenic forms of the receptor tyrosine kinase kit
J Lennartsson, T Jelacic, D Linnekin, R Shivakrupa - Stem cells, 2005 - academic.oup.com
Kit is a receptor tyrosine kinase (RTK) that binds stem cell factor. This receptor ligand
combination is important for normal hematopoiesis, as well as pigmentation, gut function …
combination is important for normal hematopoiesis, as well as pigmentation, gut function …